Sulindac
- Generic Name
- Sulindac
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17FO3S
- CAS Number
- 38194-50-2
- Unique Ingredient Identifier
- 184SNS8VUH
- Background
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver e...
- Indication
For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.
- Associated Conditions
- Ankylosing Spondylitis (AS), Colorectal Adenomas, Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Tendonitis exacerbated, Acute Subacromial bursitis, Acute supraspinatus tendinitis
- Associated Therapies
- -
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00335504
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Randomized Study of Sulindac in Oral Premalignant Lesions
- Conditions
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT00299195
- Locations
- 🇮🇳
Amrita Institute of Sciences (AIMS), Cochin, India
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇮🇳Regional Cancer Center (RCC), Trivandrum, India
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00245024
- Locations
- 🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-11
- Target Recruit Count
- 60
- Registration Number
- NCT00176618
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 375
- Registration Number
- NCT00118365
- Locations
- 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
Sulindac and Plant Compounds in Preventing Colon Cancer
- Conditions
- Locations
- 🇺🇸
Rockefeller University Hospital, New York, New York, United States
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 70
- Registration Number
- NCT00068419
- Locations
- 🇺🇸
Children's Oncology Group, Monrovia, California, United States
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00062023
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00039520
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.